A Phase I, Randomized, Placebo-Controlled, Double-Blind, Ascending-Dose And Single-Center Study To Evaluate Immunogenicity And Safety Of A Live Attenuated Tetravalent Dengue Vaccine (KD-382) In Flavivirus Antibody-Nave Healthy Adults
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Aug 2019
Price : $35 *
At a glance
- Drugs KD-382 (Primary)
- Indications Dengue
- Focus Adverse reactions; First in man; Pharmacodynamics
- Acronyms KD-382-001
- Sponsors Kaketsuken; KM Biologics
- 05 Aug 2019 Planned End Date changed from 30 Apr 2020 to 30 Sep 2020.
- 05 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Status changed from not yet recruiting to recruiting.